Official UK procurement notice
Rituximab Subcut · UK public procurement notice
Authority: The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS) (NHS & healthcare)
What is being bought
Published requirement descriptionNo description was published on the notice. See the official documents.
CPV: Pharmaceutical products
The lotProcurement structure
single lot · no lot value publishedLot #1This contract modification, effecting an extension of the Framework Agreement duration…
This contract modification, effecting an extension of the Framework Agreement duration from 1 April 2025 until 31 March 2026, has been agreed between the supplier and the Authority on behalf of NHS Scotland to meet the additional demands of the Scottish Health and Social Care sector.
This modification has been approved to maintain necessary supply due to circumstances unforeseen by the Authority in line with Regulation 72(1)(c) of the Public Contracts (Scotland) Regulations 2015.
Procedure terms & legal framework
From the official record · publisher note attached- Legal basis
- CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
- Procurement category
- Goods
- Notice status
- Awarded
- Procurement threshold
- Unspecified in notice
- Regulatory regime
- Standard
- Commercial structure
- Stand-alone contract (no framework)
- Competition type
- Competitive procedure
- GPA / WTO covered
- Unspecified in notice
- Recurring procurement
- Unspecified in notice
- First published
- 30 May 2024, 15:30 BST
- Last source update
- 1 Apr 2025, 13:00 BST
- Authority reference
NP93420- FTS notice number
2025/S 000-012236- Classification (CPV)
- Delivery area
- Official registry OCID
ocds-h6vhtk-046c75Find a Tender
- Review procedure
Economic operators should approach the contracting authority in the first instance. However, the only formal remedy is to apply to the courts:
An economic operator that suffers, or is at risk of suffering, loss, or damage attributable to a breach of duty under the Public Contracts (Scotland) Regulations 2015 or the Procurement Reform (Scotland) Act 2014, may bring proceedings in the Sheriff Court or the Court of Session.
The bringing of court proceedings against the Authority after the Framework Agreement has been entered into will not affect the Framework Agreement unless grounds for the imposition of special penalties under the Public Contracts (Scotland) Regulations 2015 can be established. Otherwise, the remedies that may be awarded by the courts where the Framework Agreement has been entered into are limited to the award of damages.
Publisher note: The estimated value(s) of the Framework Agreement referred to in Section V.2.4 covers the twenty-four (24) month contract duration and the thirty-three (33) month extension period of the Framework Agreement. (SC Ref:789206)
How it was run
Official notice- Submission deadline
- —
Timeline
1 Apr 2021 → 1 Apr 2025 · 2 dates- Contract starts1 Apr 2021, 00:00 BST
- Notice published1 Apr 2025, 13:00 BST
Commercial outcome & contract awards
Published awards, contracts and bid statistics, not a forecast| Awarded to | Value | Date | Status |
|---|---|---|---|
| Roche Products Ltd | £13,823,236 † | — | Awarded |
| Roche Products LtdNP93420 Rituximab Subcut | £15,722,106 †same award published again · counted once | — | Awarded |
Contracts
Rituximab Subcut · Roche Products Ltd
- Signed
- 28 May 2020
- Value
- £13,823,236
- Period
- … – 31 Mar 2025
- Status
- active
- Change This modification effects an extension of the Framework Agreement duration from 1 April 2025 until 31 March 2026. The modification notice is advised at Framework Agreement level only and so it does not detail individual Lots. All Terms and Conditions for the Framework Agreement remain in place., Need for modification brought about by circumstances which a diligent contracting authority/entity could not foresee: This modification is necessary to meet the additional demands of the Scottish Health and Social Care sector to maintain necessary supply due to circumstances unforeseen by the Authority, and at this time have rendered this modification necessary, in line with Regulation 72(1)(c) of the Public Contracts (Scotland) Regulations 2015.
NP93420 Rituximab Subcut · Roche Products Ltd
- Signed
- 28 May 2020
- Value
- £15,722,106
- Period
- … – 31 Mar 2025
- Status
- active
- Change This modification effects an extension of the Framework Agreement duration from 30 June 2024 until 31 March 2025. The modification notice is advised at Framework Agreement level only and so it does not detail individual Lots. All Terms and Conditions for the Framework Agreement remain in place., Need for modification brought about by circumstances which a diligent contracting authority/entity could not foresee: This modification is necessary to meet the additional demands of the Scottish Health and Social Care sector to maintain necessary supply due to circumstances unforeseen by the Authority, and at this time have rendered this modification necessary, in line with Regulation 72(1)(c) of the Public Contracts (Scotland) Regulations 2015.
Contracting authority & participating public bodies
Dispute resolution & review bodies
- Sheriff Court HouseReview body
Bidders & participating suppliers
1 commercial party on the notice- Roche Products LtdAwarded supplier
Official documents & specifications
Official links; attachments are not copiedNo document links were published on the notice.